Cancer Drug Reimbursement Study Could Ramp Up Pressure on 340B Hospitals

A new study in Health Affairs could add to the squeeze on 340B hospitals’ margins on infused cancer drugs.

A new study in Health Affairs could add to the squeeze on 340B hospitals’ margins on infused cancer drugs.

The study by health economics and public health researchers at the University of California at Berkeley found that prices paid

Read More »

340B INDUSTRY LEADER SPOTLIGHT

Daniel Palestrant, MD, CEO, par8o

Daniel Palestrant

Q: Where did you grow up?

I was born in Johannesburg, South Africa.  When I was two my parents moved to the US.  I mostly grew up in Phoenix, AZ.  

Q: Where did you go to college/graduate school?

I went to undergrad at Johns Hopkins and Medical School at Duke.

Q: What are your favorites?

Food:

Read More »

Judge Rejects Novartis’ Request to Speed Up Hearing in 340B Contract Pharmacy Lawsuit

A federal judge yesterday denied drug maker Novartis’ request to speed up a hearing on its request that the judge block the government from punishing the company over its denials of 340B pricing when health care providers use contract pharmacies

A federal judge yesterday denied drug maker Novartis’ request to speed up a hearing on its request that the judge block the government from punishing the company over its denials of 340B pricing when health care providers use contract pharmacies.

Read More »

News Alert: New Senate Bill Would Let HRSA Audit 340B Providers to See How They Use 340B Net Income

Senator Mike Braun (R-IN) has introduced legislation to let the government audit 340B entities to determine how they use net income from 340B savings.

U.S. Sen. Mike Braun (R-Ind.) introduced legislation last night to let the federal government audit 340B covered entities to determine how they use net income from drugs bought under the 340B program.

Braun filed the bill late yesterday. According

Read More »

Parties at Center of Contract Pharmacy Standoff React to HHS OIG Referral

HRSA's decision to refer six drug manufacturers to the HHS OIG has elicited a variety of reactions.

The decision by the U.S. Health Resources & Services Administration (HRSA) to refer six drug manufacturers to the U.S. Health and Human Services Department of the Office of The Inspector General (HHS OIG) for refusing to offer 340B discounts to

Read More »

With Delta Variant Persisting, Health Care Groups Struggle with Conference Planning

Many health care organizations are reconsidering plans for in-person conferences as a result of the Delta variant. The 340B Coalition is polling potential attendees regarding their preferences for the its winter conference in late January.

After an initial burst of optimism earlier this year, some health care organizations are having second thoughts about large in-person events for the remainder of 2021 and the start of the new year.  However, some groups including the 340B Coalition

Read More »

Starting Next Month, HRSA Plans to Audit Some 340B Entities Onsite for First Time Since Pandemic

HRSA says it may resume some onsite audits of 340B covered entities as early as next month, sparking concerns among some providers already battling the fallout from the Delta variant of COVID-19.

The U.S. Health Resources and Services Administration (HRSA) says it plans to resume some onsite 340B compliance audits of covered entities starting in October. This is sparking concern among 340B providers in light of crisis conditions in some states fueled

Read More »

Hospitals Urge CMS To Abandon Medicare Part B Cuts While PhRMA Presses For More Action

Hospital trade groups have lodged strong objections to CMS's proposal to maintain deep Medicare Part B reimbursement cuts, while PhRMA is suggesting even further 340B reforms.

Hospital trade groups are lodging strong objections to maintaining steep cuts in Medicare Part B drug reimbursement as part of the Fiscal Year 2022 final rule for the hospital outpatient prospective payment system (OPPS), while the trade group for brand

Read More »

Breaking News

Breaking: HRSA Refers Six Drug Companies to HHS OIG For Refusing to Offer Discounts

HRSA has referred six drug manufacturers to the HHS Office of Inspector General for refusing to offer 340B discounts in the contract pharmacy setting.

The U.S. Health Resources & Services Administration (HRSA) today referred six drug manufacturers to the U.S. Health and Human Services Department of the Office of the Inspector General (HHS OIG) regarding their refusal to offer 340B discounts to 340B covered

Read More »

U.S. Supreme Court Schedules Oral Arguments on 340B Reimbursement Case

The Supreme Court’s decision to hear the case over Medicare-related 340B cuts to hospitals surprised many observers. Oral arguments are scheduled for Nov. 30, with a decision not likely until the spring.

The U.S. Supreme Court has announced the cases it will take up this fall and 340B will be on the plate. The court recently posted its hearings schedule for the months of October through December and will hear oral

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live